M.H. Ryu

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

Anas Gazzah, Philippe L. Bédard, Cinta Hierro et al. · Annals of Oncology · 2022 · 81 citations

Pharmacy, Oncology, Pharmacology +17

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

Y-K. Kang, Changhoon Yoo, B-Y. Ryoo et al. · British Journal of Cancer · 2013 · 53 citations · Full text

Medicine, Oncology, Pharmacology +17

1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study

Kensei Yamaguchi, Y-J. Bang, Satoru Iwasa et al. · Annals of Oncology · 2020 · 44 citations · Full text

Medicine, Oncology, Surgery +17

Randomized Phase Ii Study of Capecitabine and Cisplatin with or Without Sorafenib in Patients with Metastatic Gastric Cancer: Stargate Study

Yoon‐Koo Kang, K.H. Lee, Lin Shen et al. · Annals of Oncology · 2014 · 17 citations

Medicine, Oncology, Pharmacology +16